Get the Stockscreener App
4.01
1.47%
-0.06
After Hours:
4.01
Briacell Therapeutics Corp stock is traded at $4.01, with a volume of 62,138.
It is down -1.47% in the last 24 hours and down -3.84% over the past month.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
See More
Previous Close:
$4.07
Open:
$4.07
24h Volume:
62,138
Relative Volume:
0.15
Market Cap:
$29.07M
Revenue:
-
Net Income/Loss:
$-29.01M
P/E Ratio:
-0.0829
EPS:
-48.3535
Net Cash Flow:
$-29.34M
1W Performance:
+0.25%
1M Performance:
-3.84%
6M Performance:
-49.05%
1Y Performance:
+16.91%
1-Day Range:
$3.97
$4.14
1-Week Range:
$3.61
$4.25
52-Week Range:
$0.61
$14.68
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
4.01 | 29.51M | 0 | -29.01M | -29.34M | -48.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting - The Manila Times
Aug Retail: Can BriaCell Therapeutics Corp ride the EV waveEntry Point & Smart Money Movement Alerts - baoquankhu1.vn
AI Stocks: Is Putnam Master Intermediate Income Trust stock risky to hold nowMarket Sentiment Report & Real-Time Market Trend Scan - baoquankhu1.vn
BriaCell Therapeutics: Key Catalysts on the Horizon for Investors - AD HOC NEWS
Trading (BCT) With Integrated Risk Controls (BCT:CA)Stock Traders Daily Canada - Stock Traders Daily
EPS Watch: Is BriaCell Therapeutics Corp a defensive stockEarnings Risk Summary & Smart Investment Allocation Tips - baoquankhu1.vn
BCTXZBriacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
BCTXBriacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
Basic earnings per share (basic EPS) of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
Price to earnings ratio of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
BCTXL | BriaCell Therapeutics Corp. Warrant Institutional Ownership - Quiver Quantitative
BCTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BCTXW SEC FilingsBriacell Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
BCTXW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Street Watch: Is BriaCell Therapeutics Corp a defensive stock2025 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License - National Today
BCTXZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal - Indian Pharma Post
BriaCell Restructures Soluble CD80 Program via BriaPro Deal - TipRanks
BriaCell enters asset sale to BriaPro for sCD80, receives 23.97M shares and up to $3M credit - TradingView
(BCT) Investment Performance Report (BCT:CA) - Stock Traders Daily
Is BriaCell Therapeutics Corp. stock a top pick in earnings seasonJuly 2025 Catalysts & Risk Adjusted Buy and Sell Alerts - mfd.ru
Bull Run: What is BriaCell Therapeutics Corp. Equity Warrant’s valuation compared to sector2025 Geopolitical Influence & Weekly Setup with High ROI Potential - mfd.ru
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study - Intellectia AI
BriaCell (BCTX) Expands Biologic Cancer Treatments Through New A - GuruFocus
BriaPro to Acquire BriaCell’s Soluble CD80 License in Strategic Cancer Immunotherapy Deal - TipRanks
Briacell, Briapro enter into asset purchase agreement for exclusive soluble CD80 license - marketscreener.com
BriaCell Therapeutics Brief: BriaCell and BriaPro Entering Into Asset Purchase Agreement for Exclusive Soluble CD80 License - marketscreener.com
Will BriaCell Therapeutics Corp. Equity Warrant stock maintain momentum in 2025Market Activity Report & Verified Chart Pattern Signals - mfd.ru
BriaCell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer - marketscreener.com
(BCT) Technical Patterns and Signals (BCT:CA) - Stock Traders Daily
BriaCell Wins Fifth Straight Safety Nod for Fast-Track Phase 3 Breast Cancer Trial - TipRanks
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue - marketscreener.com
Data Safety Review Board Issues Positive Safety Recommendation For BriaCell's Phase 3 Study - marketscreener.com
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - The Manila Times
BriaCell Receives Positive Recommendation from Data Safety - GlobeNewswire
BriaCell Awarded New Zealand Patent for its Whole Cell Technology - Intellectia AI
Why BriaCell Therapeutics Corp. stock could be next big winnerTrade Exit Summary & High Conviction Buy Zone Alerts - mfd.ru
What is BriaCell Therapeutics Corp. Equity Warrant s debt to equity ratioJuly 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru
Entry Recap: Will BriaCell Therapeutics Corp. stock go up in YEARTrade Risk Report & Long-Term Safe Investment Ideas - mfd.ru
Is now the right time to enter BriaCell Therapeutics Corp.2025 Fundamental Recap & Risk Controlled Daily Plans - mfd.ru
Will BriaCell Therapeutics Corp. Equity Warrant announce a stock splitJuly 2025 Rallies & Daily Volume Surge Signals - mfd.ru
Can BriaCell Therapeutics Corp. stock maintain growth trajectoryPrice Action & Free Low Drawdown Momentum Trade Ideas - mfd.ru
(BCT) Equity Trading Insights (BCT:CA) - Stock Traders Daily
Published on: 2026-02-14 21:45:18 - mfd.ru
Does BriaCell Therapeutics Corp. Equity Warrant have pricing powerMarket Activity Report & Technical Confirmation Alerts - mfd.ru
BCTX Should I Buy - Intellectia AI
BCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will BriaCell Therapeutics Corp. Equity Warrant stock outperform value stocks2025 Winners & Losers & Community Verified Swing Trade Signals - mfd.ru
Does BriaCell Therapeutics Corp. stock have upside surprise potentialJuly 2025 Momentum & Consistent Return Strategy Ideas - mfd.ru
Is now the right time to enter BriaCell Therapeutics Corp. Equity Warrant2025 Volume Leaders & Safe Capital Growth Tips - mfd.ru
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):